HCSA Community Services with support from Gilead Sciences, and Tan Tock Seng Hospital, launch first Hepatitis C elimination initiatives for ex-offender groups in Singapore

SINGAPORE, 27 July 2022 – In alignment with the World Health Organization (WHO)’s call to eliminate hepatitis C (HCV) by 2030, HCSA Community Services (HCSA), a charitable organisation that supports ex-offenders, abused teenage girls and single parents, today announced the launch of a targeted HCV elimination programme, a day ahead of World Hepatitis Day 2022.

Founded by HCSA and coordinated by HCSA Highpoint Halfway House, a residential shelter for exoffenders, the HCSA Highpoint Hepatitis C – Educate, Test, Treat! (ETT) Programme, together with the End-C Programme founded by Tan Tock Seng Hospital (TTSH), aims to provide HCV testing, education, and linkage to care servicesfor high-risk patient groups such as former drug offenders, newly released prisoners, and those in recovery from addiction. The ETT programme is a grant project supported by Gilead Sciences.

In conjunction with the ETT programme, TTSH is currently running a study with HCSA’s participants to validate the reliability and convenience of a minimally invasive point-of-care test (POCT). The POCT would provide a possibility of more convenient and accessible method using a finger-prick blood sample and saliva test. The concept of the POCT is focused on reducing the barriers to testing as it could encourage a person to test frequently and get quick results in 20 to 40 minutes. A positive result will then allow the person to seek confirmatory tests and receive earlier intervention. Confirmed active HCV participants of the ETT programme will also be given oral medication for treatment.

The findings of the ETT programme will be further implemented in the End-C Programme, which aims to gradually treat and screen other at-risk groups. One of its main goals is to ultimately encourage self-assessment of HCV risks amongst the public. The combined efforts of HCSA and TTSH to combat HCV include a newly launched Hepatitis C clinic in TTSH and the setup of a digital resource platform which grants access to education materials and a FriEnd-C Befrienders’ Toolkit to encourage positive HCV patients to complete their treatment journey. The ETT and End-C Programmes, which are running concurrently, will also focus on providing seamless access to treatment for HCV-infected patients. Both the ETT Programme and TTSH study will be conducted over a period of twelve months. Please refer to Annex A for more information.

HCV has often been described as the ‘hidden epidemic’ because new HCV infections are typically
asymptomatic until decades later when symptoms develop secondary to serious liver damage. As of this year, the WHO estimates that approximately 58 million people live with HCV worldwide with 1.5 million new infections occurring each year. As the virus is easily transmitted through blood-to-blood contact, HCV disproportionately impacts people who inject drugs. According to the Global Commission on Drug Policy, out of the 16 million people who inject drugs globally, around 10 million are currently living with HCV.
“Each at-risk patient experiences a different challenge to achieving recovery, ranging from
socioeconomic constraints to stigmatisation associated with the mode of virus transmission,” says Dr Yew Kuo Chao, Senior Consultant, Gastroenterology and Clinical Hepatology, Tan Tock Seng Hospital. “We hope to drive the elimination of HCV by providing linkage to care for patients and introducing minimally invasive testing and simplified treatment methods. If successful, we hope to expand this service to the wider population and benefit more people in the process.”
Without medical intervention, HCV can progress to lifelong chronic liver conditions. Despite the
severity of HCV, there remains a general lack of awareness and an attitude of indifference towards liver health in Singapore. According to the recent Liver Index Study conducted by Gilead Sciences, less than half (42%) of the Singaporean general public recognise that viral hepatitis is one of the key causes of liver failure in the world. Furthermore, only 65% of respondents have attended a health screening in the past two years, even though majority (91%) agree that regular screening is essential to maintaining liver health. If left unaddressed, this could hinder public efforts to control the spread of HCV locally.

“The World Health Organization has set a global target to eliminate viral hepatitis as a public health threat by 2030. Through the Liver Index Study, we have identified critical knowledge gaps and attitudes of the general local public towards liver health. Gilead Sciences is working with community partners to support high-impact initiatives which address existing barriers and challenges to HCV elimination efforts,” says Stanley Li, General Manager, Hong Kong, Singapore and Malaysia, Gilead Sciences. “Microelimination projects like the HCSA Highpoint Hepatitis C – Educate, Test, Treat! (ETT) Programme, with its focus on high-risk groups for which treatment and prevention interventions can be delivered more efficiently, is a starting point that we believe will translate into more positive impact for local communities.”

As part of the combined programme, patients will also be given educational materials and telephone consultations by the Tan Tock Seng Hospital Gastroenterology and Hepatology Department, to assist them in their treatment journey. This is complemented by HCSA’s FriEnd-C Befriender Programme, an integrated support system to guide patients that are HCV positive and ensure that they do not fall out of the programme and complete the treatment journey.

To sustain and drive further education among target patient groups, HCSA will also be conducting

educational campaigns through a range of initiatives, including talks at HCSA Highpoint Halfway House and other halfway houses in Singapore.
“As the first halfway house in Singapore to champion and host this first of its kind HCV elimination
programme, we are committed to driving awareness and education on HCV among vulnerable
groups,” said Kim Lang Khalil, Chief Executive Officer, HCSA Community Services. “We are confident that the ETT and End-C Programmes will empower at-risk groups, remove existing barriers to HCV care, and enable all individuals to live their lives to the fullest.”

About HCSA
HCSA is a charitable organisation with the Institution of Public Character (IPC) status and a member of the National Council of Social Service (NCSS). The organisation was launched in 1996 as a halfway house for recovering drug addicts and ex-offenders. Today, their work has expanded to include teenage girls who have undergone the complex trauma of abuse and single parents with limited support. HCSA operates with a team of dedicated staff, volunteers, corporate and community partners, as they continue to serve the most vulnerable in society, to give them a future and a hope. HCSA’s mission is to empower these vulnerable populations through their signature programmes. Find out more at https://hcsa.org.sg/.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Find out more at https://www.gilead.com/.
About Tan Tock Seng Hospital
Tan Tock Seng Hospital (TTSH) is the flagship hospital of the National Healthcare Group and part of Singapore’s Public Healthcare System. As a pioneering hospital with strong roots in the community for over 177 years, TTSH is recognised as the People’s Hospital, serving a resident population of 1.4 million living in Central Singapore. Together with 70 community partners and 80 community health posts, it brings care beyond the hospital into the community as an integrated care organisation – Central Health. As one of the largest multi-disciplinary hospitals in Singapore, TTSH operates more than 1,700 beds with centres of excellence including the National Centre for Infectious Diseases (NCID), Institute for Geriatrics & Active Ageing (IGA), NHG Eye Institute (NHGEI), and TTSH Rehabilitation Centre. Find out more at https://www.ttsh.com.sg/.
Media Contact
FINN Partners for HCSA Community Services
Download the PDF here.


Stay updated, make a difference!